Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Bovijn J., Krebs K., Chen C-Y., Boxall R., Censin JC., Ferreira T., Pulit SL., Glastonbury CA., Laber S., Millwood IY., Lin K., Li L., Chen Z., Milani L., Smith GD., Walters RG., Mägi R., Neale BM., Lindgren CM., Holmes MV.
SOST variants that mimic therapeutic inhibition of sclerostin for osteoporosis are associated with higher risk of cardiovascular disease.